Zivo Bioscience Inc (ZIVO) - Total Assets
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) holds total assets worth $663.60K USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ZIVO cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Zivo Bioscience Inc - Total Assets Trend (2003–2025)
This chart illustrates how Zivo Bioscience Inc's total assets have evolved over time, based on quarterly financial data. See ZIVO net assets for net asset value and shareholders' equity analysis.
Zivo Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Zivo Bioscience Inc's total assets of $663.60K consist of 60.5% current assets and 39.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $259.79K | 39.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Zivo Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZIVO stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zivo Bioscience Inc's current assets represent 60.5% of total assets in 2025, a decrease from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 10.1% of total assets in 2025, up from 9.1% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is inventory at 39.2% of total assets.
Zivo Bioscience Inc Competitors by Total Assets
Key competitors of Zivo Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Zivo Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.80 | 0.04 |
| Quick Ratio | 0.03 | 0.80 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.81 Million | $-406.38K | $-11.48 Million |
Zivo Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Zivo Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.76 |
| Latest Market Cap to Assets Ratio | 25.02 |
| Asset Growth Rate (YoY) | -59.6% |
| Total Assets | $663.60K |
| Market Capitalization | $16.61 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zivo Bioscience Inc's assets at a significant premium (25.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Zivo Bioscience Inc's assets decreased by 59.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zivo Bioscience Inc (2003–2025)
The table below shows the annual total assets of Zivo Bioscience Inc from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $663.60K | -59.61% |
| 2024-12-31 | $1.64 Million | +195.68% |
| 2023-12-31 | $555.72K | -73.82% |
| 2022-12-31 | $2.12 Million | -76.39% |
| 2021-12-31 | $8.99 Million | +3983.12% |
| 2020-12-31 | $220.18K | -40.39% |
| 2019-12-31 | $369.39K | -10.23% |
| 2018-12-31 | $411.51K | -90.23% |
| 2017-12-31 | $4.21 Million | +471.02% |
| 2016-12-31 | $737.29K | +914.44% |
| 2015-12-31 | $72.68K | -28.65% |
| 2014-12-31 | $101.86K | -95.32% |
| 2013-12-31 | $2.17 Million | +829.22% |
| 2012-12-31 | $234.00K | -49.51% |
| 2011-12-31 | $463.49K | +36.35% |
| 2010-12-31 | $339.92K | -15.40% |
| 2009-12-31 | $401.80K | -7.66% |
| 2008-12-31 | $435.14K | +58.32% |
| 2007-12-31 | $274.85K | -14.62% |
| 2006-12-31 | $321.92K | -51.22% |
| 2005-12-31 | $659.94K | +1142.03% |
| 2004-12-31 | $53.13K | +439.65% |
| 2003-12-31 | $9.85K | -- |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more